Male Breast Cancer

The patient was treated with tamoxifen and adjuvant chest wall + axillary radiotherapy. At follow-up, he remains disease-free with a good quality of life. This case highlights the importance of early suspicion in male breast lesions and emphasizes individualized management integrating tumor biology, stage, and patient factors.

While prostate cancer is the most frequent urological cancer in these families, increasing access to and awareness of genetic testing may better inform future studies about these cancer phenotypes. We reinforce that the systematic assessment of personal and family cancer history in these patients may assist in identifying individuals who could benefit from genetic evaluation and tailored surveillance strategies for carriers and their families.

This is consistent with the near-universal estrogen receptor (ER) positivity that characterizes MBC clinically. This atlas provides the first cellular and transcriptional reference for the normal male breast and a resource for investigating sex differences in mammary biology, germline susceptibility variant interpretation, and modeling breast malignancies.

Tumor sequencing confirmed both germline variants but showed microsatellite stability and no loss of heterozygosity, arguing against a causal role of MSH6. This case illustrates how PRS, in combination with moderate-risk variants, like those in CHEK2, may drive early-onset MBC and highlights the need to incorporate polygenic models into risk assessment and counseling.

To our knowledge, this is only the fourth case of its kind and the only one to provide gross imagery and two separate confirmatory pathology reports. Implications of the findings include continued preferred management via surgical excision, remaining awareness of rare tumors, and additional evidence for the possible prevalence of rare male breast tumors that may have been previously not considered.

Our findings suggest a unique genomic and immunologic landscape in MaBC requiring a sex-informed approach and provide candidate therapeutic targets and mechanisms of resistance.

Although drug therapy and radiation therapy were recommended after the operation, the patient was under observation due to his advanced age. A brief literature review is presented in this section.

As the inaugural germline genomic investigation of MaBC in a Han Chinese population, this work reveals clinically actionable alterations with diagnostic and therapeutic implications. These discoveries not only advance our understanding of MaBC's molecular architecture but also underscore the critical need for dedicated research into this malignancy.

Management strategies for male breast cancer generally parallel female protocols, despite unique biological features. By integrating considerations of benign and malignant conditions, this review underscores the importance of tailored evaluation, risk assessment, and individualized care for males, while identifying knowledge gaps to inform future research and improve outcomes in this under-recognized population.

Oncotype diagnosis (DX) testing indicated a low chemotherapy benefit, leading to adjuvant therapy with tamoxifen...The prompt detection of the suspicious mass, culminating in effective early-stage treatment, proved crucial to this patient's favorable prognosis, in contrast to the common trend of delayed diagnoses and their less promising outcomes. Accordingly, strengthening public awareness and professional training is essential to optimize management and improve outcomes in men with breast cancer.

Median overall survival (OS) 131 months (1-, 2-, 5-, 10-year OS: 95%, 93%, 73%, 53%). This long-term cohort highlights the predominance of hormone-receptor positivity, the infrequency of germline mutations, and moderate survival rates, informing patient management and guiding future studies.

It accurately separated patients with good, intermediate, and poor performance at high statistical significance. Development of a MBC-specific prediction tool remains desirable.